Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)

– In a preclinical HCH model, TYRA-300 demonstrated increases in long bone length and binding against the HCH altered protein- -TYRA remains on track to submit ACH Investigational New Drug Application (IND) in 2H24- CARLSBAD, Calif., July 2, 2024 /PRNewswire/ — Tyra Biosciences, Inc….

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks